"The research and development expenditures in the December quarter relate to three clinical trials which have completed expensive the clinical stage. Hence, future expenditures will be lower." .... now that clinical stage costs for all 3 trials are out of the way future 1/4ly outflows could be more in the 750-950k region. Taking R&D $1.6m coming into account they still have about $2.3mill cash. So will not need to consider CR until end of Financial Year. Having said that A LOT of headline news to come within that period.... BIT likes to get the formalities out of the way before the BIG announcements.
"The research and development expenditures in the December...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.003(5.45%) |
Mkt cap ! $52.33M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.5¢ | $24.61K | 431.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 41188 | 2 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.8¢ |
Change
0.003 ( 7.41 %) |
||||
| Open | High | Low | Volume | ||
| 5.5¢ | 5.9¢ | 5.5¢ | 128584 | ||
| Last updated 15.28pm 13/05/2024 ? | |||||
| BIT (ASX) Chart |